维普中文期刊产品整合服务
7篇 您的检索式:作者名="Gideon M Hirschfield"
    题名 作者 年代 出处 被引量
1Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes显示文摘AIM To establish the impact of portal hypertension(PH) on wait-list/post-transplant outcomes in patients with polycystic liver disease(PCLD) listed for liver transplantation. METHODS A retrospective single-centre case controlled study of consecutive patients listed for liver transplantation over 12 years was performed from our centre. PH in the PCLD cohort was defined by the one or more of following parameters:(1) presence of radiological or endoscopic documented varices from our own centre or the referral centre;(2) splenomegaly(> 11 cm) on radiology inabsence of splenic cysts accounting for increased imaging size;(3) thrombocytopenia(platelets < 150 × 109/L); or(4) ascites without radiological evidence of hepatic venous outflow obstruction from a single cyst. RESULTS Forty-seven PCLD patients(F: M = 42: 5) were listed for liver transplantation(LT)(single organ, n = 35; combined liver-kidney transplantation, n = 12) with 19 patients(40.4%) having PH. When comparing the PH group with non-PH group, the mean listing age(PH group, 50.6(6.4); non-PH group, 47.1(7.4) years; P = 0.101), median listing MELD(PH group, 12; non-PH group, 11; P = 0.422) median listing UKELD score(PH group, 48; non-PH group, 46; P = 0.344) and need for renal replacement therapy(P = 0.317) were similar. In the patients who underwent LT alone, there was no difference in the duration of ICU stay(PH, 3 d; non-PH, 2 d; P = 0.188), hospital stay length(PH, 9 d; non-PH, 10 d; P = 0.973), or frequency of renal replacement therapy(PH, 2/8; non-PH, 1/14; P = 0.121) in the immediate post-transplantation period. CONCLUSION Clinically apparent portal hypertension in patients with PCLD listed for liver transplantation does not appear to have a major impact on wait-list or peri-transplant morbidity.Neil Rajoriya Dhiraj Tripathi Joanna A Leithead Bridget K Gunson Sophie Lord James W Ferguson Gideon M Hirschfield 2016World Journal of Gastroenterology2016,22,45:2
2C-reactive protein:a critical update显示文摘Mark b pepys Gideon M Hirschfield 2003J Clin Invest2003,111,:1
3C-reactive protein: a critical update显示文摘Mark B Pepys Gideon M Hirschfield 2003Clin Invest2003,111,12:1
4Targeting C- reactive protein for the treatment of cardiovascular disease 显示文摘Pepys MB Gideon M Hirschfield 2006Nature2006,440,7088:1
5Chronic pancreatitis 显示文摘Gideon M Hirschfield Alexander E Gimson 2007Medicine2007,35,6:1
6Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and In- adequate Response to Ursodeoxycholic Acid 显示文摘Gideon M Hirschfield Andrew Mason Luketic V 2014Gastroentrology2014,5085,01:1
7丙型肝炎病毒感染的管理显示文摘黄病毒属RNA病毒丙型肝炎病毒(HCV)慢性感染是肝脏疾病的一个主要原因。英国卫生部估计,该国HCV慢性感染者约2百万人——其中50%并不知道自身感染了这种病毒。流行情况在不同人群中有所差别:献血者为0.04%,泌尿生殖门诊患者为1%,静脉吸毒者可达到50%。一名全科医师平均处置1800名患者就有8~20名丙型肝炎。如果这些患者得以诊治,一半以上可获病毒清除。我们概括了肝脏病学的这一领域,着重强调HCV感染的危险因素、筛查人群以及慢性感染患者的专业治疗。Kathryn L Nash Ian Bentley Gideon M Hirschfield 张月宁(译) 2009英国医学杂志中文版2009,12,5:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费